C4 Therapeutics (CCCC) Operating Income (2019 - 2026)
C4 Therapeutics' quarterly Operating Income came in at -$27.8 million in Q1 2026, up 4.73% year-on-year from -$26.5 million in Q1 2025, and down 20.05% quarter-over-quarter from -$23.1 million in Q4 2025.
C4 Therapeutics has reported Operating Income for 8 years, with the latest figure at -$27.8 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 4.73% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$113.8 million (up 2.33% YoY), and the FY2025 full-year result was -$115.2 million, up 3.67% from the prior year.
- Operating Income for Q1 2026 stood at -$27.8 million, down from -$23.1 million in the prior quarter.
- The five-year high for Operating Income was -$21.4 million in Q2 2024, with the low at -$38.3 million in Q4 2022.
- Average Operating Income over 5 years is -$31.2 million, with a median of -$31.4 million recorded in 2022.
- Year-over-year, Operating Income plunged 151.02% in 2022 and jumped 42.92% in 2024.
- Tracing CCCC's Operating Income over 5 years: stood at -$38.3 million in 2022, then climbed by 2.26% to -$37.4 million in 2023, then slipped by 0.75% to -$37.7 million in 2024, then jumped by 38.62% to -$23.1 million in 2025, then retreated by 20.05% to -$27.8 million in 2026.
- The last three Operating Income figures came in at -$27.8 million (Q1 2026), -$23.1 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -27.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.79 Mn |
| Dec 31, 2025 | -23.15 Mn |
| Sep 30, 2025 | -34.41 Mn |
| Jun 30, 2025 | -28.50 Mn |
| Mar 31, 2025 | -29.16 Mn |
| Dec 31, 2024 | -37.71 Mn |
| Sep 30, 2024 | -28.24 Mn |
| Jun 30, 2024 | -21.44 Mn |
| Mar 31, 2024 | -32.22 Mn |
| Dec 31, 2023 | -37.43 Mn |
| Sep 30, 2023 | -27.81 Mn |
| Jun 30, 2023 | -37.57 Mn |
| Mar 31, 2023 | -36.23 Mn |
| Dec 31, 2022 | -38.29 Mn |
| Sep 30, 2022 | -32.49 Mn |
| Jun 30, 2022 | -27.38 Mn |
| Mar 31, 2022 | -31.37 Mn |
| Dec 31, 2021 | -15.26 Mn |
| Sep 30, 2021 | -24.25 Mn |
| Jun 30, 2021 | -22.12 Mn |
| Mar 31, 2021 | -20.51 Mn |
| Dec 31, 2020 | -18.90 Mn |
| Sep 30, 2020 | -18.35 Mn |
| Jun 30, 2020 | -10.86 Mn |
| Mar 31, 2020 | -12.34 Mn |
| Dec 31, 2019 | -10.50 Mn |
| Sep 30, 2019 | -10.00 Mn |